Short interest in Nurix Therapeutics Inc (NASDAQ:NRIX) decreased during the last reporting period, falling from 12.17M to 12.16M. This put 18.75% of the company's publicly available shares short.

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...